The global pharmaceutical sector is undergoing a massive structural shift capable of completely reshaping the multi-billion-dollar market for targeted oncology therapies. At the center of the global investment community’s attention is a new experimental lung cancer drug created through the joint efforts of Akeso and Summit Therapeutics. In late-stage clinical trials, this molecule demonstrated the ability to reduce the risk of patient death by 34%. Such a breakthrough has triggered a wave of discussions on Wall Street and among the world’s leading oncologists. We at FinancialMediaGuide emphasize that these recorded efficacy metrics place the biotechnology sector on a trajectory of fierce competition, threatening the long-standing leadership of established blockbusters in the therapeutic segment. For large institutional investors, the current situation serves as a signal for a large-scale re-evaluation of assets across the entire pharmaceutical industry.
According to the official abstract theses published ahead of the annual American Society of Clinical Oncology (ASCO) meeting, the innovative bispecific antibody ivonescimab was used in combination with traditional chemotherapy. This treatment regimen allowed patients with verified squamous non-small cell lung cancer to live an average of four months longer compared to those who received a standard combination of modern immunotherapy and chemotherapy. Median survival in the study group reached 27.9 months versus 23.7 months in the control cohort. This result achieved full statistical significance. According to FinancialMediaGuide analysts, the key challenge in commercially evaluating this success lies in the geographic boundaries of the tests, as the Phase 3 trial was conducted exclusively across medical centers in China. Our expert opinion is that extrapolating these data to the global population requires maximum caution, as ethnic factors and regional characteristics of drug metabolism in Asia can significantly influence ultimate therapeutic ratios.
The molecular design of ivonescimab combines simultaneous targeting of the PD-1 protein – replicating the mechanism of action of Merck’s best-selling anti-tumor drug Keytruda – and vascular endothelial growth factor (VEGF), which is involved in the mechanism of Roche’s well-known therapeutic agent Avastin. This dual-targeting concept has drawn polarized assessments from stock market experts. A number of analysts predict that bispecific antibodies will inevitably replace the monospecific solutions of past generations. Their opponents point to recent painful failures of other high-profile projects, including TIGIT receptor inhibitors, which also demonstrated outstanding results in intermediate stages but completely disappointed the market in final-stage trials. We at FinancialMediaGuide believe that excessive investor optimism often shatters against the complex biological architecture of solid tumors, which are capable of rapidly activating compensatory survival pathways when multiple signaling cascades are blocked simultaneously.
Sharp shifts in market sentiment instantly impacted the market value of the American entity Summit Therapeutics, which holds the exclusive license for the commercial promotion of ivonescimab outside the Chinese market. Over the past two years, the company’s stock price soared by nearly 600% amid reports that the drug controls tumor progression more effectively than the recognized standard, Keytruda. However, the subsequent decline in share value demonstrated investor fear regarding the strict requirements of Western regulators. We at FinancialMediaGuide view this as a natural market reaction. To secure approval from the US Food and Drug Administration (FDA), it is not enough for biotech companies to show progression-free survival. The regulator demands solid proof of extending overall survival, whereas historical experience with older VEGF blockers shows that local reduction in tumor size rarely translated into long-term patient survival.
Additional methodological questions were raised by the fact that in the Chinese Harmoni-6 study, patients in the control group lived an average of six months longer than historical standards for squamous cell carcinoma. Such high survival rates in the comparison group raise doubts about the representativeness of the patient sample and indicate a potential selection of more stable participants. Medical analysts believe that the specific profile of patients in China, who are historically more sensitive to combinations of PD-1 and VEGF inhibitors, could have artificially inflated the final metrics. To verify ivonescimab’s real therapeutic advantage, the sector needs the results of the ongoing global multicenter Harmoni-3 trial, which is tailored to Western clinical standards.
The safety profile of the bispecific molecule also imposes certain limitations on its commercial prospects. Squamous non-small cell lung cancer is heavily associated with long-term smoking, and tumor foci typically form around large pulmonary vessels. Blocking the VEGF factor disrupts natural vascular wall regeneration mechanisms, which exponentially increases the risk of fatal pulmonary hemorrhages. During the Harmoni-6 tests, hemorrhagic manifestations of varying severity were recorded in nearly a quarter of patients taking ivonescimab, which was double the rate of the control group. Less than 3% of these cases were classified as severe, while with standard therapy using tislelizumab, this figure stood at 1%. We at FinancialMediaGuide emphasize that even a minimal increase in the frequency of critical side effects within global trials could force regulators to significantly narrow the patient population for whom this drug can be prescribed, thereby shrinking its potential market share.
The massive financial interests of manufacturers are driven by the desire to displace Keytruda and Bristol Myers Squibb’s Opdivo as standard first-line therapies. The financial stakes are colossal, considering that Keytruda’s annual sales revenue exceeded 30 billion dollars, covering more than forty different medical indications. Attempts to capture a share of this giant market have triggered a boom in mergers and acquisitions within the oncology segment, where the volume of licensing agreements for bispecific molecules reached 30 billion dollars last year, matching historical records of previous years. The largest players, including Merck itself, are actively buying up development rights for similar platforms to protect their long-term cash flows from technological obsolescence.
Despite aggressive marketing, ivonescimab will have to develop in an unprecedentedly crowded competitive environment. Unlike the era when the first checkpoint inhibitors emerged, the current market offers alternative highly effective platforms, among which antibody-drug conjugates (ADCs) stand out. At the current ASCO session, a consortium of Merck and Kelun presented data on a new ADC-class drug that managed to reduce the risk of lung tumor progression by 65% in similar local tests. Such a pronounced therapeutic effect from adjacent technological platforms deprives bispecific antibodies of their status as the sole alternative to existing treatment protocols.
At Financial Media Guide, we predict that the future evolution of the oncology drug market rules out scenarios of monopoly dominance by a single therapeutic agent. We believe the industry is moving toward creating personalized combination protocols where bispecific molecules will occupy a strictly defined niche. The developers of ivonescimab, Summit and Akeso, are unlikely to fully replicate Keytruda’s commercial trajectory across all therapeutic areas; however, successful completion of international trials will allow them to establish a foothold in the complex squamous non-small cell lung cancer segment. To maintain business profitability, we recommend that pharmaceutical corporations diversify investments between bispecific antibody platforms and ADC developments, focusing on creating flexible pricing offers for public health insurance systems. The winners in this race will be the companies capable of demonstrating a balance between increasing human life expectancy and tightly controlling the toxic side effects of therapy.
